The estimated Net Worth of A. Sinclair Dunlop is at least $30 Million dollars as of 28 June 2024. Mr. Dunlop owns over 900 units of Apellis Pharmaceuticals Inc stock worth over $5,156,274 and over the last 5 years he sold APLS stock worth over $24,615,568. In addition, he makes $235,535 as Independent Director at Apellis Pharmaceuticals Inc.
A has made over 29 trades of the Apellis Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 900 units of APLS stock worth $11,871 on 28 June 2024.
The largest trade he's ever made was selling 162,873 units of Apellis Pharmaceuticals Inc stock on 18 May 2021 worth over $8,557,347. On average, A trades about 18,876 units every 47 days since 2019. As of 28 June 2024 he still owns at least 134,418 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Dunlop stock trades at the bottom of the page.
A. Sinclair Dunlop is Independent Director of the Company. Mr. Dunlop is a co-founder of venture capital fund Epidarex Capital and has served as its Managing Partner since July 2010. Since 2005, Mr. Dunlop has served as the Managing Partner of venture capital fund Masa Life Science Ventures, LP. Mr. Dunlop currently serves on the board of directors of several private companies. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also received an M.A. with Honors in political economy from the University of Glasgow and an M.A. in international relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University.
As the Independent Director of Apellis Pharmaceuticals Inc, the total compensation of A Dunlop at Apellis Pharmaceuticals Inc is $235,535. There are 13 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.
A Dunlop is 48, he's been the Independent Director of Apellis Pharmaceuticals Inc since 2010. There are 13 older and 8 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
A's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois und Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: